Business Context and Reporting Period
This Form 8-K Current Report was filed by Zai Lab Limited on June 1, 2021. The filing discloses a material definitive agreement entered into on May 28, 2021, between Zai Lab (Hong Kong) Limited and Mirati Therapeutics, Inc.
Key Financial Metrics and Transaction Terms
The filing details a collaboration and license agreement for the development and commercialization of MRTX849 (adagrasib) in China, Macau, Hong Kong, and Taiwan. Key financial terms include:
- Upfront Payment: $65.0 million payable by Zai Lab to Mirati.
- Milestone Payments: Up to $273.0 million contingent on clinical, regulatory, and sales milestones.
- Royalties: Tiered percentages ranging from the high teens to low twenties percent on annual net sales in the licensed territory.
- Financial Performance: The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures.
Material Changes
The primary material change is the acquisition of exclusive rights to research, develop, manufacture, and commercialize adagrasib in the Greater China region. This represents a significant strategic expansion of Zai Lab's oncology portfolio through a partnership with Mirati Therapeutics.
Outlook, Risks, and Contingencies
Management Commentary: The agreement allows Zai Lab to leverage Mirati's asset while retaining exclusive rights in the licensed territory, with Mirati retaining rights outside the region and certain co-commercialization rights within it.
Termination and Risks:
- Zai Lab may terminate the agreement with 12 months' prior notice.
- Either party may terminate upon material breach or bankruptcy events.
- Mirati may terminate if Zai Lab challenges licensed patent rights.
- The agreement terminates on a product-by-product and region-by-region basis based on patent expiration, 10 years after first commercial sale, or regulatory exclusivity expiration.
Investor Verification Checklist
- Verify the impact of the $65.0 million upfront payment on Zai Lab's current cash position and liquidity.
- Review the full text of the collaboration agreement (to be filed as an exhibit) for specific definitions of milestones and royalty reduction circumstances.
- Assess the clinical development status of MRTX849 (adagrasib) and the timeline for potential commercialization in the licensed territory.
- Confirm the company's ability to fund future milestone payments and operational costs associated with the new collaboration.